Novum Pharmaceutical Research Services is expanding its services in North America by consolidating Lambda Therapeutic Research’s Toronto, Canada clinic and bioanalytical laboratory into Novum operations. This follows the 2019 acquisition of Novum by Lambda.
 
The enhanced Novum organization will serve global clients throughout its operations in Pennsylvania, North Dakota, Nevada and Toronto, Canada. The Canadian site, which was founded in 2010, offers additional capacity to provide clinical services including Phase I (First-in-Human), Pharmacokinetics (PK), Pharmacodynamic (PD), Drug-Drug Interaction studies (DDI), Dose Escalation (SAD/MAD), Safety, Tolerability, Dose Ranging and Patient PK studies.
 
Novum Canada’s bioanalytical lab has developed over 400 assays involving small and large molecules in its GLP compliant facility. Novum Canada’s scientists routinely develop and validate methods and analyze over 15,000 samples a month, including proprietary methods for NCE and generic molecules with sub picogram detection, endogenous, chiral and hormonal assays.